These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 36490241)

  • 21. A Retrospective Observational Study of Factors Affecting the Efficacy of Concurrent Prescription of Naldemedine for Opioid-Induced Constipation Caused by Oxycodone Tablets.
    Yamada M; Jimaru Y; Torii S; Mitsuba N; Takahashi K
    Biol Pharm Bull; 2023; 46(12):1826-1831. PubMed ID: 38044102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
    Nee J; Zakari M; Sugarman MA; Whelan J; Hirsch W; Sultan S; Ballou S; Iturrino J; Lembo A
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1569-1584.e2. PubMed ID: 29374616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
    Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan.
    Takata K; Nakazawa M; Honda K; Hashimoto S
    Support Care Cancer; 2022 May; 30(5):3943-3954. PubMed ID: 35044484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naldemedine: A Review in Opioid-Induced Constipation.
    Blair HA
    Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.
    Webster LR; Nalamachu S; Morlion B; Reddy J; Baba Y; Yamada T; Arjona Ferreira JC
    Pain; 2018 May; 159(5):987-994. PubMed ID: 29419653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Webster LR; Yamada T; Arjona Ferreira JC
    Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis.
    Ishii K; Yamashita H; Yamaguchi M; Komatsu Y; Ryu E; Morishita S; Matsuo K; Kamada M; Ikeda T; Ashizawa K; Hara T
    Intern Med; 2020 Jan; 59(2):293-296. PubMed ID: 31534081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripherally-active mu-opioid receptor antagonists for constipation in critically ill patients receiving opioids: A case-series and a systematic review and meta-analysis of the literature.
    Umbrello M; Venco R; Palandri C; Racagni M; Muttini S
    Neurogastroenterol Motil; 2023 Dec; 35(12):e14694. PubMed ID: 37869768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
    Wild J; Yamada T; Arjona Ferreira JC; Hale M
    Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid withdrawal syndrome developing after long-term administration of naldemedine.
    Ishida M; Uchida N; Yabuno A; Hasegawa K; Mizunuma N; Takahashi T; Onishi H
    Palliat Support Care; 2022 Dec; 20(6):897-899. PubMed ID: 35543119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naldemedine is associated with earlier defecation in critically ill patients with opioid-induced constipation: A retrospective, single-center cohort study.
    Nishiyama S; Uchino S; Sasabuchi Y; Masuyama T; Lefor AK; Sanui M
    PLoS One; 2024; 19(1):e0295952. PubMed ID: 38170714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine.
    Hashizume J; Shiojiri K; Ryu E; Kawauchi Y; Hasegawa K; Ezaki N; Yamashita H; Ishii K; Harasawa H; Nakamura T; Sasaki H; Kodama Y
    Biol Pharm Bull; 2021; 44(8):1081-1087. PubMed ID: 34334493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Management of Opioid-Induced Constipation in Cancer and Advanced Illness: A Meta-Analysis.
    Jesuyajolu DA; Abubakar AK; Kowe T; Ogunlade S; Abioye AI; Tangeman J; Latuga N; Omotayo MO
    J Pain Symptom Manage; 2024 Apr; 67(4):e285-e297. PubMed ID: 38092261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study.
    Hiruta E; Fujita Y; Imai H; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Nishiba H; Mogi J; Kotake M; Koizuka S; Minato K
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833451
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacological Profile of Naldemedine, a Peripherally Acting
    Kanemasa T; Koike K; Takase K; Arai T; Nakamura A; Morioka Y; Hasegawa M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):438-444. PubMed ID: 32169839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Naldemedine for the Use of Management of Opioid Induced Constipation.
    Urits I; Patel A; Kiernan HC; Clay CJ; Monteferrante N; Jung JW; Berger AA; Kassem H; Hasoon J; Kaye AD; Kaye AM; Viswanath O
    Psychopharmacol Bull; 2020 Jul; 50(3):97-118. PubMed ID: 32733114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naldemedine-induced opioid withdrawal with restlessness as the predominant symptom in a palliative care setting.
    Sato R; Ishida M; Uchida N; Sakimoto T; Yamaguchi T; Ooya Y; Takahashi T; Onishi H
    Palliat Support Care; 2023 Oct; 21(5):957-959. PubMed ID: 37350233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
    Ozaki A; Kessoku T; Iwaki M; Kobayashi T; Yoshihara T; Kato T; Honda Y; Ogawa Y; Imajo K; Higurashi T; Yoneda M; Taguri M; Yamanaka T; Ishiki H; Kobayashi N; Saito S; Ichikawa Y; Nakajima A
    Trials; 2020 Jun; 21(1):453. PubMed ID: 32487150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.